Evidence map›Paper›PMID 30451962›Full record

ArticleScientific reports2018

The efficacy of serum cell death biomarkers for diagnosing biliary tract cancer.

Mitsuru Sugimoto, Kazumichi Abe, Manabu Hayashi, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Mitsuru SugimotoDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan. kita335@fmu.ac.jp.
Kazumichi AbeDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Manabu HayashiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Tadayuki TakagiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Rei SuzukiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Naoki KonnoDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Hiroyuki AsamaDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Yuki SatoDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Hiroki IrieDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Ko WatanabeDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Jun NakamuraDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Hitomi KikuchiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Yuichi WaragaiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Mika TakasumiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Minami HashimotoDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Takuto HikichiDepartment of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.
Yoshihiro NozawaDepartment of Pathology, Shirakawa Kousei General Hospital, Shirakawa, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Fukushima Medical University · JPFukushima Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we determined the efficacy of the cell death biomarker cytokeratin 18 for diagnosing biliary tract cancer (BTC). We recruited 36 patients with BTC (Malignant group) and 45 patients with benign biliary tract disease (Benign group) for this study. We used M30 and M65 as cell death biomarkers. M30 levels indicate apoptosis, and M65 levels indicate both apoptosis and necrosis. M30 and M65 levels were significantly higher in the Malignant group than in the Benign group (142.4 ± 117.0 vs 48.9 ± 71.2 U/l, P < 0.001; 1513.3 ± 837.4 vs 882.2 ± 831.2 U/l, P = 0.001). The diagnosability of M30 was the highest of the four markers (CEA, CA19-9, M30, M65) (cut-off value: 74.429 U/l, sensitivity: 72.2%, specificity: 77.1%, AUC: 0.771). The sensitivity of M30 (cut-off value: 74.429 U/l) was significantly higher than that of biliary cytology (76% (19/25) vs 12% (3/25), P < 0.001), and the accuracy of M30 was significantly higher than that of biliary cytology (78.3% (36/46) vs 52.2% (24/46), P = 0.015). The sensitivity of M30 (cut-off value: 74.429 U/l) was significantly higher than that of biliary cytology and brush cytology (72.4% (21/29) vs 24.1% (7/29), P < 0.001). In conclusion, cell death biomarkers were increased in patients with BTC, and M30 could efficiently diagnose BTC.

Indexed as

Cell DeathAgedBiliary Tract NeoplasmsBiomarkers, TumorCase-Control StudiesFemaleFollow-Up StudiesHumansKeratin-18MalePeptide FragmentsPrognosisROC CurveBiomarkers, TumorKeratin-18KRT18 protein, humanM30 cytokeratin-18 peptide, humanPeptide Fragments

Identifiers

PMID30451962
PMCPMC6243019
OpenAlexW2900610226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.